Cargando…
Epigenetic modifications of interleukin-6 in synovial fibroblasts from osteoarthritis patients
Osteoarthritis (OA) is the most common degenerative disease of the synovial joint. The synovial membrane is responsible for the inflammatory reaction leading to the secretion of macrophage-derived pro-inflammatory cytokines, such as IL-6. Suppressing IL-6 over-expression in synovial fibroblasts (SF)...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5337936/ https://www.ncbi.nlm.nih.gov/pubmed/28262826 http://dx.doi.org/10.1038/srep43592 |
_version_ | 1782512470716317696 |
---|---|
author | Yang, Fei Zhou, Song Wang, Chuandong Huang, Yan Li, Huiwu Wang, You Zhu, Zhenan Tang, Jian Yan, Mengning |
author_facet | Yang, Fei Zhou, Song Wang, Chuandong Huang, Yan Li, Huiwu Wang, You Zhu, Zhenan Tang, Jian Yan, Mengning |
author_sort | Yang, Fei |
collection | PubMed |
description | Osteoarthritis (OA) is the most common degenerative disease of the synovial joint. The synovial membrane is responsible for the inflammatory reaction leading to the secretion of macrophage-derived pro-inflammatory cytokines, such as IL-6. Suppressing IL-6 over-expression in synovial fibroblasts (SF) is a promising method to prevent OA development and progression, in which the prerequisite is the elucidation of the molecular mechanisms underlying IL-6 over-expression in SF. Currently, there are few reports concerning epigenetic modifications in IL-6 in OA SF. In the present study, we attempted to investigate this phenomenon. SF over-expressing IL-6 was collected from OA patients. DNA hypomethylation and histone hyperacetylation were observed in the IL-6 promoter regions in OA SF compared with normal SF. No differences in the status of H3K9 di-methylation, H3K27 tri-methylation and H3K4 tri-methylation were observed in the IL-6 promoter regions between normal and OA SF. DNA (cytosine-5-)-methyltransferase 3 alpha (Dnmt3a) overexpression and anacardic acid (histone acetyltransferase inhibitor) treatment increased DNA methylation and decreased histone acetylation in the IL-6 promoter, and IL-6 over-expression in OA SF was suppressed. These observations provide deeper insight into the pathogenesis of OA and can be used to design new drugs and develop new therapeutic methods to treat OA. |
format | Online Article Text |
id | pubmed-5337936 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-53379362017-03-08 Epigenetic modifications of interleukin-6 in synovial fibroblasts from osteoarthritis patients Yang, Fei Zhou, Song Wang, Chuandong Huang, Yan Li, Huiwu Wang, You Zhu, Zhenan Tang, Jian Yan, Mengning Sci Rep Article Osteoarthritis (OA) is the most common degenerative disease of the synovial joint. The synovial membrane is responsible for the inflammatory reaction leading to the secretion of macrophage-derived pro-inflammatory cytokines, such as IL-6. Suppressing IL-6 over-expression in synovial fibroblasts (SF) is a promising method to prevent OA development and progression, in which the prerequisite is the elucidation of the molecular mechanisms underlying IL-6 over-expression in SF. Currently, there are few reports concerning epigenetic modifications in IL-6 in OA SF. In the present study, we attempted to investigate this phenomenon. SF over-expressing IL-6 was collected from OA patients. DNA hypomethylation and histone hyperacetylation were observed in the IL-6 promoter regions in OA SF compared with normal SF. No differences in the status of H3K9 di-methylation, H3K27 tri-methylation and H3K4 tri-methylation were observed in the IL-6 promoter regions between normal and OA SF. DNA (cytosine-5-)-methyltransferase 3 alpha (Dnmt3a) overexpression and anacardic acid (histone acetyltransferase inhibitor) treatment increased DNA methylation and decreased histone acetylation in the IL-6 promoter, and IL-6 over-expression in OA SF was suppressed. These observations provide deeper insight into the pathogenesis of OA and can be used to design new drugs and develop new therapeutic methods to treat OA. Nature Publishing Group 2017-03-06 /pmc/articles/PMC5337936/ /pubmed/28262826 http://dx.doi.org/10.1038/srep43592 Text en Copyright © 2017, The Author(s) http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
spellingShingle | Article Yang, Fei Zhou, Song Wang, Chuandong Huang, Yan Li, Huiwu Wang, You Zhu, Zhenan Tang, Jian Yan, Mengning Epigenetic modifications of interleukin-6 in synovial fibroblasts from osteoarthritis patients |
title | Epigenetic modifications of interleukin-6 in synovial fibroblasts from osteoarthritis patients |
title_full | Epigenetic modifications of interleukin-6 in synovial fibroblasts from osteoarthritis patients |
title_fullStr | Epigenetic modifications of interleukin-6 in synovial fibroblasts from osteoarthritis patients |
title_full_unstemmed | Epigenetic modifications of interleukin-6 in synovial fibroblasts from osteoarthritis patients |
title_short | Epigenetic modifications of interleukin-6 in synovial fibroblasts from osteoarthritis patients |
title_sort | epigenetic modifications of interleukin-6 in synovial fibroblasts from osteoarthritis patients |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5337936/ https://www.ncbi.nlm.nih.gov/pubmed/28262826 http://dx.doi.org/10.1038/srep43592 |
work_keys_str_mv | AT yangfei epigeneticmodificationsofinterleukin6insynovialfibroblastsfromosteoarthritispatients AT zhousong epigeneticmodificationsofinterleukin6insynovialfibroblastsfromosteoarthritispatients AT wangchuandong epigeneticmodificationsofinterleukin6insynovialfibroblastsfromosteoarthritispatients AT huangyan epigeneticmodificationsofinterleukin6insynovialfibroblastsfromosteoarthritispatients AT lihuiwu epigeneticmodificationsofinterleukin6insynovialfibroblastsfromosteoarthritispatients AT wangyou epigeneticmodificationsofinterleukin6insynovialfibroblastsfromosteoarthritispatients AT zhuzhenan epigeneticmodificationsofinterleukin6insynovialfibroblastsfromosteoarthritispatients AT tangjian epigeneticmodificationsofinterleukin6insynovialfibroblastsfromosteoarthritispatients AT yanmengning epigeneticmodificationsofinterleukin6insynovialfibroblastsfromosteoarthritispatients |